In this study, Muehlich and colleagues generated novel inhibitors with improved potency for inhibition of MRTF-A and SRF for HCC therapy and demonstrated a correlation between inhibition of TRPM7 activity, SRF activity, and HCC cell proliferation and senescence. The gene discussed is SRF; the disease is hepatocellular carcinoma.